Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Revenue $361.0 million, up 36% year over year, in third-quarter 2026
- ➤2026 revenue guidance raised to $1.36 to $1.37 billion, 38% to 40% growth
- ➤Shield tests reached 83,000, up 246% year over year
- ➤Oncology tests reached 117,000, up 58% year over year
- ➤Full-year free cash flow burn forecast increased to $205 million to $220 million
Expert Statements
Helmy Eltoukhy, Co-founder and co-CEO of Guardant Health
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”
AmirAli Talasaz, Co-founder and co-CEO of Guardant Health
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening
Get started
Create a free account to read the full story.